Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "CD52" patented technology

CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene. CD52 is present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes were derived. It also is found on monocytes and dendritic cells. Further, it is found within the male genital tract and is present on the surface of mature sperm cells.

Epitesticular corpuscle-specific sorting markers and epitesticular corpuscle sorting kits and methods

The present application relates to the technical field of extracellular vesicle sorting, and particularly relates to a epididymal body specific sorting marker, and an epididymal body sorting kit and method. The present application finds that CD52 can be used as a specific marker for sorting epididymal bodies. The present application is the first time to directly separate epididymal bodies from human seminal plasma, the sample is easy to obtain, and the operation process is non-invasive, safe, and the separation path is simple and easy to operate. In addition, it provides a method for the separation of other tissue-specific EV subpopulations. The present application can contribute to further explore the effect of epididymal bodies on sperm function and improve sperm function, and epididymal bodies as a marker have great potential for clinical diagnosis and treatment.
Owner:HUAZHONG UNIV OF SCI & TECH

Selective targeting of host CD70+ alloreactive cells to prolong allogeneic car t cell persistence

PendingUS20260146098A1Immunoglobulin superfamilyVertebrate antigen ingredientsDiseaseAntigen binding
Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.
Owner:ALLOGENE THERAPEUTICS INC